BH17 A case of talquetamab-induced onychomadesis with associated palmoplantar keratoderma and desquamation

Claire Quigley,Al Mutasim Al Qassabi,Lisa Murphy,Amy Long,Irene Timoney,Rory Barry,Sophie Diong,Susan O’Gorman

DOI: https://doi.org/10.1093/bjd/ljae090.164

IF: 11.113

2024-06-28

British Journal of Dermatology

Abstract:Abstract Herein we present the case of a 59-year-old woman who presented to our department with shedding of nails on all 10 fingers and toes, as well as desquamation of the skin on the palms of her hands and soles of her feet. She had a background history of relapsing refractory multiple myeloma and had not responded to multiple other lines of therapy. However, she had biochemical and clinical remission of her multiple myeloma with a new monoclonal antibody agent, talquetamab. She presented to our clinic with significant nail and skin changes that occurred 2 weeks into treatment with talquetamab. She reported shedding of the nails on all 10 fingers and toes, with recurrent cycles of regrowth and shedding. She also reported increased thickened scale and peeling of the skin on the palms of her hands and soles of her feet. Examination revealed onychomadesis of all nails and toenails as well as palmoplantar keratoderma and desquamation. Talquetamab is a bispecific monoclonal antibody targeting human CD3 surface antigen, and GPRC5D tumour-associated antigen. It was approved as a conditional monotherapy for relapsing refractory multiple myeloma in August 2022. In trials, nail-related adverse events occurred in 57% of patients receiving talquetamab and skin-related adverse events occurred in 67% of recipients. To our knowledge, there has been only one other case report of onychomadesis described in relation to talquetamab therapy. It is postulated that the target protein GPRC5D is also present in nails, with talquetamab treatment leading to nail matrix arrest and subsequent nail shedding. These changes have impacted on our patient’s quality of life, including affecting her manual dexterity. Treatment with ultrapotent topical steroids has provided only modest benefit.

dermatology